Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors

Authors

Nicolas Sayegh, Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Juliet Yirerong, Division of Cardiology, Department of Internal Medicine, Yale Bridgeport Hospital, Bridgeport, CT, USA.
Neeraj Agarwal, Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Daniel Addison, Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA.
Michael Fradley, Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jorge Cortes, Division of Hematology and Oncology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Neal L. Weintraub, Division of Cardiology, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Nazish Sayed, Department of Vascular Surgery, Cardiovascular Research Institute, Stanford University, Palo Alto, CA, USA.
Girindra Raval, Division of Hematology and Oncology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Avirup Guha, Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA. aguha@augusta.edu.

Document Type

Article

Publication Title

Current cardiology reports

Abstract

PURPOSE OF REVIEW: To provide a detailed overview of cardiovascular adverse events associated with the use of tyrosine kinase inhibitors across different tumor types. RECENT FINDINGS: Despite an undeniable survival advantage of tyrosine kinase inhibitors (TKIs) in patients with hematologic or solid malignancies, the accompanying off-target cardiovascular adverse events can be life-threatening. In patients with B cell malignancies, the use of Bruton tyrosine kinase inhibitors has been associated with atrial and ventricular arrhythmias, as well as hypertension. Cardiovascular toxic profiles are heterogeneous among the several approved breakpoint cluster region (BCR)-ABL TKIS. Notably, imatinib might be cardioprotective. Vascular endothelial growth factor TKIs, constituting the central axis in the treatment of several solid tumors, including renal cell carcinoma and hepatocellular carcinoma, have strongly been associated with hypertension and arterial ischemic events. Epidermal growth factor TKIs as therapy for advanced non-small cell lung cancer (NSCLC) have been reported to be infrequently associated with heart failure and QT prolongation. While tyrosine kinase inhibitors have been demonstrated to increase overall survival across different types of cancers, special consideration should be given to cardiovascular toxicities. High-risk patients can be identified by undergoing a comprehensive workup at baseline.

First Page

269

Last Page

280

DOI

10.1007/s11886-023-01845-2

Publication Date

4-1-2023

Recommended Citation

Sayegh, Nicolas; Yirerong, Juliet; Agarwal, Neeraj; Addison, Daniel; Fradley, Michael; Cortes, Jorge; Weintraub, Neal L.; Sayed, Nazish; Raval, Girindra; and Guha, Avirup, "Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors" (2023). All Research. 42.
https://scholar.bridgeporthospital.org/all_research/42

Identifier

36795308 (pubmed); NIHMS1918472 (mid); PMC10392782 (pmc); 10.1007/s11886-023-01845-2 (doi); 10.1007/s11886-023-01845-2 (pii)